Subject to the satisfaction of customary closing conditions, including regulatory clearances, the deal is anticipated to close shortly
Accord Plasma, a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100 per cent of Prothya Biosolutions Belgium and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based primarily in the Netherlands and Belgium. Subject to the satisfaction of customary closing conditions, including regulatory clearances, the deal is anticipated to close shortly.
Prothya Biosolutions, with primary operations in Amsterdam and Brussels and plasma collection centres across Hungary, employs approximately 1,200 people. The company is one of Europe’s largest plasma fractionators. Formed in 2021 through the integration of Plasma Industries Belgium, originally linked to the Belgian Red Cross, and Sanquin Plasma Products, formerly a part of the Sanquin Blood Supply Foundation, Prothya brings over 60 years of experience in plasma collection and the development of PDMPs.
Binish Chudgar, Chairman, Intas and Accord, stated, “We are delighted to expand our plasma business through the acquisition of Prothya Biosolutions. Combined with our fractionation capabilities in India, this positions us to create a truly global plasma platform—serving patients worldwide with critical, often under-prescribed, therapies.”
Nir Epstein, CEO, Prothya, commented, “Over the past four years, we’ve expanded into new markets, advanced critical therapies, established our own plasma collection network in Hungary, and supplied plasma derivatives to some of the world’s leading PDMP companies—all while building a stronger, more resilient organization. I want to thank our dedicated team for their unwavering commitment to our patients. I believe Accord is the right company to support Prothya and its people in the next phase of growth and global expansion.”
The global market for PDMPs—particularly IVIG (intravenous immunoglobulin)—is currently valued at $30 billion and is expected to reach $50 billion by 2035. This acquisition will give Intas access to significant additional fractionation capacity, supported by Accord’s commercial footprint spanning 85 countries.
